Mosaic Therapeutics, a British startup born out of research collaboration between the Wellcome Sanger Institute and the Netherlands Cancer Institute, is dedicated to revolutionizing cancer treatment by reinventing the traditional approach to target and drug discovery. They utilize artificial intelligence to prioritize anti-cancer targets and identify patient groups most likely to respond to treatments. With active programs across various oncology indications and disease biology pathways, Mosaic Therapeutics aims to develop novel therapies by combining large dataset mining with experimental approaches. Their goal is to save lives by targeting cancer vulnerabilities and helping clients develop more effective medicines.